News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Boehringer Ingelheim Corporation FY Profit Slumps 50 Pct, Hit by Generics
April 5, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - Boehringer Ingelheim, the world's largest unlisted drugmaker, saw net income slump by half in 2010 as cheaper generic copies of some of its best-selling pharmaceuticals came to market.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Boehringer Ingelheim
MORE ON THIS TOPIC
Layoff Tracker
Amgen lays off around 40 employees
July 26, 2026
·
70 min read
·
BioSpace Editorial Staff
Drug Development
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
July 24, 2026
·
3 min read
·
Gabrielle Masson
IPO
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
July 24, 2026
·
3 min read
·
Tristan Manalac
Regulatory
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
July 24, 2026
·
4 min read
·
Annalee Armstrong
